Skip to main content

Table 2 ANC recovery in Induction 1 and Consolidation

From: A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

  Pegfilgrastim 6 mg (n = 42) Filgrastim 5 μg/kg/day (n = 41)
Induction 1   
   Number of patients starting cycle 42 41
   Number of patients (%) with SN 42 (100%) 41 (100%)
   Number of patients (%) with ANC recoverya 35 (83%) 32 (78%)
   Median time to ANC recoveryb 22 days 22 days
Range 16, 55 19, 62
Difference between medians (95% CI) 0.0 (-1.9 to 1.9)
Consolidation   
   Number of patients starting cycle 22 24
   Number of patients (%) with SN 20 (91%) 21 (88%)
   Number of patients (%) with ANC recoverya 18 (82%) 23 (96%)
   Median time to ANC recoveryb 17 days 16.5 days
Range 1, 57 1, 51
Difference between medians (95% CI) 0.5 (-1.1 to 2.1)
  1. ANC, absolute neutrophil count; SN, severe neutropenia (ANC <0.5 × 109/L); CI, confidence interval.
  2. aIncludes patients whose ANC remained at or above 0.5 × 109/L
  3. bNumber of days from start of chemotherapy until the first of 2 consecutive days with ANC ≥ 0.5 × 109/L; time to recovery was set to 1 day for patients whose ANC remained at or above 0.5 × 109/L